AUPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aurinia Pharmaceuticals is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 available. The company’s latest quarter was strong, but the stock just sold off sharply on leadership-change concerns, and the technical setup is still weak. I would not chase it today; the better call is to hold and wait for clearer price stability or a better entry.
AUPH closed at 15.15, essentially flat versus the prior close, but the broader recent move was sharply negative with a -6.80% regular-session decline. The MACD histogram is below zero and expanding negatively, which points to weakening momentum. RSI_6 at 35.31 is close to oversold but not yet a strong rebound signal. Moving averages are converging, suggesting a possible inflection, but current trend strength is still poor. Key levels: support at 14.74 and 14.18, resistance at 16.54 and 17.10. The stock is trading below pivot resistance, so the near-term trend remains cautious rather than bullish.
["Q1 revenue grew 24.4% year over year to about $77.7 million", "Q1 GAAP EPS came in at $0.25, beating expectations", "Net income rose sharply to $34.36 million", "LUPKYNIS sales remain a strong driver of growth", "Options sentiment is bullish, with low put-call ratios"]
["The stock dropped sharply despite strong earnings, likely due to leadership-change concerns", "MACD is negative and weakening, showing poor momentum", "RSI is not yet giving a strong buy signal", "No strong hedge fund or insider buying trend is present", "No recent congress trading data or influential buying support was reported"]
In the latest reported quarter, AUPH delivered strong growth. Revenue in 2026 Q1 was $77.7 million, up 24.4% year over year, and net income was $34.36 million. The financial snapshot for 2025/Q4 also showed revenue up 28.81% YoY to $77.11 million, EPS up sharply to 1.53, and net income rising dramatically. Gross margin slipped slightly to 88.59%, but overall profitability and growth remain strong. This is a solid operating trend, especially for a growth-oriented biotech name.
No analyst rating or price target trend data was provided, so there is no clear evidence of recent Wall Street upgrades or downgrades. Based on the available data, the pros view would likely focus on strong revenue/EPS growth and improving profitability, while the cons view would focus on the post-earnings selloff, leadership-change concerns, and lack of confirmed price momentum.
